Lessons Learnt from Emerging Viruses: (Coronavirus and Influenza A Virus)

Outline

- Coronavirus Background
- SARS Outbreak
 - Cause of the 2002-2003 SARS Outbreak
 - SARS-CoV
 - discovery, diagnostics, transmission
 - Origin of SARS-CoV In Humans
- Influenza A virus background
 - Evolution and ecology
 - Pandemics
 - Past, present



Coronavirus



Coronaviruses Naturally Infect Many Species





















TM

ronaviruses, Host Range and Disease

Virus	Host	Major Disease		
HCoV-229E	human	respiratory infection		
HCoV-NL63	human	respiratory infection		
TGEV	pig	enteritis and respiratory infection		
PRCoV pig	respirat	tory infection		
FIPV	cat	peritonitis, systemic infection		
FECoVcat	enteriti	enteritis		
CCoV	dog	enteritis		
HCoV-OC43	human	respiratory infection		
SARS-CoV	human	respiratory infection, enteritis		
	bat/civet			
BCoV	cattle	enteritis		
TCoV	turkey	enteritis		
RCoV	rat	respiratory infection		
HEV	pig	respiratory infection,		
		encephalomyelitis		
MHV	mouse	respiratory infection, enteritis,		
		hepatitis, encephalitis		
TDV	chickon	necripatory infaction		

oronavirus Spike

- Corona" appearance eceptor binding
- Host range
- Nembrane fusion
- Neutralizing antibodies



Severe Acute Respiratory Syndrome (SARS)

- utbreak of "atypical neumonia"
- 2002-2003
- apid progression to ARD
- entilator required
- larming death rate
- erson-to-person ansmission



Emergence of SARS



November 2002

Guangdong Province Southern China



Total of 8,098 cases of SARS and 774 deaths in 30 countries

Spread from Hotel M, Hong Kong February 2003



SARS-The Disease

Symptoms

- Fever
- Dry cough
- Diarrhea
- Acute interstitial pneumonia
- 2-10 day incubation period
- 20% intensive care
- 10% case fatality rate
- Seroconversion
- 2-4 weeks post-onset
- Transmission
- respiratory droplets



Symptoms of SARS



JAMA, June 4, 2003 – Vol. 289, No. 21

Clinical Outcome

- 20% admitted to ICU
- 5% required mechanical ventilation
- 10% died
- ncreased risk of death or ICU admission if:
 - Increased age
 - < 60 yo: 6.8%
 - > 60 yo: 55.0%
 - Co-morbidity
 - High LDH
 - High neutrophil count

Tsui et al. EID 2003; 9: 1064-1069 Fowler et al. JAMA 2003; 290: 367-373 Lew et al. JAMA 2003; 290: 374-380 Chan et al. Thorax 2003;58:686-689 Choi et al. Ann Int Med 2003;139:715-723

The Hunt for the Causative Agent of SARS

- 1. Ruled out known respiratory viruses
- 2. Inoculated cells with clinical specimen



+ clinical specimen: oropharyngeal washes respiratory specimen sputum lung biopsy kidney biopsy

*CPE seen only in Vero and FRhK-4

Figure 1. Ksiazek et al. 2003 NEJM 348:1953-1966

RS-Coronavirus

- I CoV isolated from SARS tients'
- Lungs, sputum, feces, etc.
- Grown in monkey kidney
 - Vero and pRHMK
- serological cross reaction
- SARS-CoV not previously circulated in humans
- ome distantly related to known oVs.
- 's postulates fulfilled



Figure 2. Ultrastructural characteristics of SARS-Associated Coronavirus Grown in Vero E6 cells.

In a short period of time....

- Virus detected
- Virus amplified
- Virus identified
- Sequenced
- Koch's postulates

Laboratory diagnosis: st Generation tests: March 28

T-PCR for P gene

ndirect immunofluorescence serology using virus infected cells

courtesy of J. M. Peiris





V.

Problems Providing Laboratory Diagnostics During an Outbreak

- o time to evaluate tests in advance; valuate "on the run"
- valanche of specimens: 200/ day
- o / little clinical information available in eal time" to help evaluate results
- nrealistic expectations
- nknown risk to laboratory workers



et al. Lancet 2003; 361: 2



Figure 4: Sequential quantitative RT-PCR for SARS-associated coronavirus in nasopharyngeal aspirates of 14 SARS patients

Transmission of SARS

- Positive samples: respiratory samples, stool, blood, urine, conjunctival secretions
- Droplet transmission
 - Respiratory-droplet
 - Fecal-droplet (?)
- Contact transmission
 - Direct > indirect
- Period of transmissibility
 - Symptom onset to at least 10 days after fever resolution*
 - *virus detectable but no reported transmission



http://www.who.int/csr/sars/en/WHOconsensus.pdf

Spread of SARS

pitals

- or amplifiers of virus
- 6 of people infected were HCW

Travel

- nternational flights
- 37 positive individuals
- ghts led to spread
- >60 cases exported by air



Transmission in the Face of Precautions

- cumstances:
- Severely ill patients
 - Shedding high titer
- Close contact
- Aerosol generating procedures
- ential Exposures:
- High level of airborne virus
 - Improper N95 respirators (non fit-tested)
- Break in containment
 - For example, improper removal of PPE



ARS coronavirus: Where did it come from?

ONOTIC TRANSMISSION: Viruses genetically related to SARS-CoV isolated from Himalayan palm civet cats.

n live animal markets SARS-CoV-like virus Soncurrently identified

•Y. Guan *et al.*, *Science* 302, 276 (2003).

NOt found in wild civet

•L. L. Poon et al., J. Virol. 79, 2001 (2005



nanges in Spike Important in Emergence of SARS-CoV?



What is the natural reservoir of SARS-CoV?

ese horseshoe bats: Viruses genetically related to S-CoV have been isolated from animals.

RS-CoV 39% RT-PCR 34% N antibody



ossible Genesis of SARS Outbreak

orseshoe bat



Direct zoonosis

? Intermediate

et al.,

Palm civet





- SARS-CoV antibodies Science 370: 297
 - -40% of wild animal traders
 - -20% of slaughterers
 - -5% of vegetable traders

Influenza A Virus



- 16 distinct HA's +1
 - ◆ (H1-H16)
- 9 distinct NA's +1
 - ◆ (N1-N9)
- Nomenclature
 - A/Chicken/WI/5/78 (H7N7)



Thin Section EM. T. Noda, et al, Nature 439



Influenza A Ecology and Emergence of Strains with Pandemic Potential



tural Distribution of HA and NA

Hemagglutinin (HA)

Human	Other		Aquatic
Beings	Mammals		Birds
•	(•
CR 00	ß		Ş
CQ 90			iyo a
CC 20		P	\$
	\mathcal{A}		ţ.
Zoonotic			iyo -
			i de la companya de l
Zoonotic			i de la constante de la consta
			i de la companya de l
Zoonotic			\$
			i

Neuraminidase (NA)

	Human	Other	Aquatic
	Beings	Mammals	Birds
N1	66 0 5	\mathcal{G}	iyon a she
N2	CR 07	Ģ	i de la companya de l
N3			i de la companya de l
N4			res and a second
N5			res and the second seco
N6			i de la companya de l
N7	Zoonotic		iya katala kata
N8	CR 09	1	iya katala katal
N9			iy -

man Influenza A Virus Evolution



genic Shift







• TM

Intigenic Shift and Previous Human Pandemics



- eassortment between 2 coinfecting strains
- eappearance of a previous strain



Pigs Are "Mixing Vessels " for Influenza A Viruses


olecular Mechanism of Mixing Vessel



Emergence of Novel H1N1 Causes Pandemic

Influenza Positive Tests Reported to CDC by U.S. WHO/NREVSS Collaborating Laboratories, National Summary, 2008-09



New H1N1 Causes Out of Season Pediatric Deaths

Number of Influenza-Associated Pediatric Deaths by Week of Death:

2005-06 season to present



s of 4 October 2009, more than 375,000 laboratory onfirmed cases of pandemic influenza H1N1 2009 and over

TM

ere did the 2009 H1N1 pandemic virus come from?



Swine Influenza A Virus in North America



olution of Human 209 H1N1 Virus

eumann, T. Noda, and Y. Kawaoka. rgence and pandemic potential of e-origin H1N1 influenza virus. ure 459 (7249):931-939, 2009.



Figure 4 | **Genesis of swine-origin H1N1 influenza viruses.** In the late 1990s, reassortment between human H3N2, North American avian, and classical swine viruses resulted in triple reassortant H3N2 and H1N2 swine viruses that have since circulated in North American nig populations. A triple

Emerging and Re-emerging Diseases (NIAID)

o I—Pathogens Newly gnized in the Past Two Decades • Enterovirus 71

- anthamebiasis
- stralian bat lyssavirus
- pesia, atypical
- tonella henselae
- lichiosis
- cephalitozoon cuniculi
- cephalitozoon hellem
- erocytozoon bieneusi
- ndra or equine morbilli virus
- man herpesvirus 8
- man herpesvirus 6
- vovirus B19

Group II—Re-emerging Pathogens

- Clostridium difficile
- Mumps virus ۲
- Streptococcus, Group A
- Staphylococcus aureus

Group III—Agents with Bioterrorism Potential

See the full list of <u>NIAID Category A, B, and</u> C Priority Pathogens.

Most Recent

- Middle East Respiratory Syndrome-Coronavirus (MERS-CoV)
- H7N9-Influenza A Virus

MERS Epidemiology



Clinical Disease Course

SARS

- 1. Transmission -aerosol, fomites
- 2. Acute Infection
 - -virus replication in lung
 -"cytokine storm"
 -mixed inflammatory infiltrates
 -developing lung damage (viral and host)
 -SARS-CoV specific IgG
- 3. Non-Severe cases (70-80%) -decrease titer -improved chest x-ray
- 4. Severe cases (20-30%)
 - -intubation
 - -ARDS
 - -hypoxemia
 - -mortality (10% total)

MERS

- 1. Transmission -aerosol, fomites?
- 2. Acute Infection
 - -virus replication in lung (and kidney?)
 -probably "cytokine storm"
 -mixed inflammatory infiltrates
 -developing lung damage (viral and host)
 -MERS-CoV specific IgG
- 3. Non-Severe cases (50%?) -decrease titer -improved chest x-ray
- 4. Severe cases (50%?)
 - -intubation
 - -ARDS
 - -hypoxemia
 - -mortality (50% total)

?

MERS Clinical spread



-Spread from some unknown reservoir to people (Camels/Bats suspected) -Spread from person to person in hospital settings

-Spread by travel, either vacation or for treatment

MERS-CoV replicates efficiently and causes MERS-like linical and pathological symptoms in Rhesus Macaques

S-CoV replicates in Rhesus Macaques



ncent Munster et al NEJM, 2013.









Coronavirus Phylogeny



ained at the Health Protection Agency has been tentatively named as London1_novel CoV 2012. The phylogenetic tree was If fastTree software, using the maximum-likelihood method with general time-reversible model of nucleotide substitution. Is were obtained with 1_000 replicates. Coronavirus groups are shown on the right hand side of the tree, with 1, 2 and 3 to Alpha, Beta and Gammacoronaviruses respectively.

(partial NSP12)



(Partial RdRp)

Coronavirus Phylogeny



.

oonotic H7N9 Influenza Outbreak

February		March		April		Мау		June		July		unknown month of onset		Total	
cases	deaths	cases	deaths	cases	deaths	cases	deaths	cases	deaths	cases	deaths	cases	deaths	cases	deaths
2	2	30	12	88	7	3	0	0	0	2	0	10	23	135	44

- dentified unique H7N9 virus in people in late March ovel subtype for humans
- Antigenic shift -> Pandemic potential
 equence of first viruses available April 1
 cases to date

volution of H7N9



/lutations In H7 HA Important in Zoonosis/Transmission

ep sequencing shows mixed population of virus genome in human isolate R. Fouchier and J. Richt collaboration



Discussion Questions

- disease of animals important to humans?
- Why/Why not
- Examples
- do we know SARS-CoV was new to humans?
- t profession was dramatically affected by SARS?
- t are mechanisms of evolution of influenza A virus?
- the new human H1N1 pandemic virus composed tirely of swine influenza A virus gene segments?
- MERS-CoV and H7N9 serious threats?

Koch's Postulates

- microorganism must be found in abundance in all organisms suffering from the disease, but should not be found in healthy organisms.
- microorganism must be isolated from a diseased organism and prown in pure <u>culture</u>.
- cultured microorganism should cause disease when introduced into healthy organism.
- microorganism must be reisolated from the inoculated, diseased experimental host and identified as being identical to the original specific causative agent.